Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
Neovasc Inc. (NASDAQ, TSX: NVCN) reported a record revenue of $818,000 for Q2 2022, marking a 29% increase year-over-year. The company advanced its COSIRA II clinical trial, enrolling 40 patients and receiving FDA approval for a protocol supplement. Neovasc has initiated direct sales in the UK, enhancing its market presence. Total expenses decreased by 8% to approximately $8.8 million, contributing to reduced operating losses of approximately $8.2 million. Neovasc ended Q2 2022 with about $37.6 million in cash.
- Record revenue of $818,000, a 29% increase year-over-year.
- Successful enrollment progress in the COSIRA II trial.
- FDA approved protocol supplement, expanding patient eligibility in the trial.
- Initiated direct sales in the UK, enhancing market strategies.
- Total expenses decreased by 8%, improving financial efficiency.
- Operating losses at approximately $8.2 million, despite reduced expenses.
VANCOUVER and MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the second quarter ended June 30, 2022.
Recent Highlights
- Generated revenues of
$818,000 , a quarterly record and a year-over-year increase of29% over the second quarter of 2021. - Advanced enrollment in the COSIRA II trial with 40 patients enrolled and 21 patients randomized across 10 sites.
- COSIRA II protocol supplement was approved by the FDA, more than doubling the total number of patients and adding specific patient groups eligible and allowed for treatment in the trial.
- Accelerated direct sales in the United Kingdom as of July 1, 2022 and added Neovasc sales reps.
- Announced and highlighted an additional third-party publication supporting the Reducer device.
“I am very pleased with the progress our team made advancing our value creation strategies, which resulted in another quarter of record revenues,” said Fred Colen, President and Chief Executive Officer. “In Europe, we followed up our successes with reimbursement by creating a direct sales team in the UK which will advance Reducer as a viable treatment for refractory angina in that key market. In the important US market, enrollment in the pivotal COSIRA II trial is progressing well, and we received more good news when the FDA approved a protocol supplement which doubles the pool of eligible patients to be enrolled and studied. We look forward to equally strong performance in the second half of 2022.”
Financial Results for the Second quarter Ended June 30, 2022
For the three months ended June 30, 2022, revenues increased by
The cost of goods sold for the three months ended June 30, 2022 was
Total expenses for the three months ended June 30, 2022 were approximately
The operating losses and comprehensive losses for the three months ended June 30, 2022 were approximately
The Company ended the quarter with approximately
As of August 9, 2022, after the effect of the share consolidation, the Company had 2,743,143 Common Shares issued and outstanding.
Conference Call and Webcast Information
Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International) and reference Conference ID 13730925. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.
About Neovasc
Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2011, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.
| NEOVASC INC. | ||||
| Unaudited Condensed Interim Consolidated Statements of Financial Position | ||||
| (Expressed in U.S. dollars) | ||||
| June 30, | December 31, | |||
| 2022 | 2021 | |||
| ASSETS | ||||
| Current assets | ||||
| Cash and cash equivalents | 37,631,734 | 51,537,367 | ||
| Accounts receivable | 1,637,796 | 1,369,455 | ||
| Finance lease receivable | - | 43,543 | ||
| Inventory | 1,265,831 | 1,480,077 | ||
| Prepaid expenses and other assets | 363,511 | 787,734 | ||
| Total current assets | 40,898,872 | 55,218,176 | ||
| Non-current assets | ||||
| Restricted cash | 466,377 | 469,808 | ||
| Right-of-use asset | 310,104 | 456,339 | ||
| Property and equipment | 197,061 | 182,041 | ||
| Deferred loss on 2020 derivative warrant liabilities | 1,795,604 | 4,300,484 | ||
| Deferred loss on 2021 derivative warrant liabilities | 8,261,167 | 9,898,475 | ||
| Total non-current assets | 11,030,313 | 15,307,147 | ||
| Total assets | 51,929,185 | 70,525,323 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current liabilities | ||||
| Accounts payable and accrued liabilities | 4,018,627 | 4,629,163 | ||
| Lease liabilities | 215,317 | 273,145 | ||
| 2019 Convertible notes | - | 38,633 | ||
| 2020 Convertible notes, warrants and derivative warrant liabilities | - | 40,587 | ||
| Total current liabilities | 4,233,944 | 4,981,528 | ||
| Non-Current Liabilities | ||||
| Lease liabilities | 176,692 | 272,652 | ||
| 2019 Convertible notes | - | 6,548,796 | ||
| 2020 Convertible notes, warrants and derivative warrant liabilities | 106,413 | 6,088,728 | ||
| 2021 Derivative warrant liabilities | 48,927 | 405,508 | ||
| 2022 Convertible notes | 11,795,150 | - | ||
| Total non-current liabilities | 12,127,182 | 13,315,684 | ||
| Total liabilities | 16,361,126 | 18,297,212 | ||
| Equity | ||||
| Share capital | 441,081,488 | 439,873,457 | ||
| Contributed surplus | 41,841,815 | 40,355,952 | ||
| Accumulated other comprehensive loss | (6,229,804 | ) | (7,885,024 | ) |
| Deficit | (441,125,440 | ) | (420,116,274 | ) |
| Total equity | 35,568,059 | 52,228,111 | ||
| Total liabilities and equity | 51,929,185 | 70,525,323 | ||
| NEOVASC INC. | |||||||||
| Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss | |||||||||
| For the three and six months ended June 30, 2022 and 2021 | |||||||||
| (Expressed in U.S. dollars) | |||||||||
| For the Three Months Ended | For the Six Months Ended | ||||||||
| 30-Jun | 30-Jun | ||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||
| REVENUE | 818,060 | 633,068 | 1,428,807 | 1,084,862 | |||||
| COST OF GOODS SOLD | 157,927 | 109,106 | 294,219 | 181,499 | |||||
| GROSS PROFIT | 660,133 | 523,962 | 1,134,588 | 903,363 | |||||
| EXPENSES | |||||||||
| Selling expenses | 1,395,275 | 832,812 | 2,214,171 | 1,470,791 | |||||
| General and administrative expenses | 3,137,194 | 5,042,804 | 6,140,724 | 10,335,373 | |||||
| Product development and clinical trials expenses | 4,341,666 | 3,740,887 | 7,611,216 | 8,362,315 | |||||
| 8,874,135 | 9,616,503 | 15,966,111 | 20,168,479 | ||||||
| OPERATING LOSS | (8,214,002 | ) | (9,092,541 | ) | (14,831,523 | ) | (19,265,116 | ) | |
| OTHER (EXPENSE)/INCOME | |||||||||
| Interest and other income | 51,655 | 39,733 | 69,618 | 49,753 | |||||
| Interest and other expense | (389,425 | ) | (278,154 | ) | (739,265 | ) | (318,563 | ) | |
| (Loss)/gain on foreign exchange | (20,525 | ) | 15,057 | (9,808 | ) | (20,238 | ) | ||
| Unrealized gain on warrants, derivative liability | |||||||||
| warrants and convertible notes | 612,981 | 2,809,340 | 461,638 | 15,259,393 | |||||
| Realized (loss)/gain on exercise or conversion and | |||||||||
| extinguishment of warrants, derivative liability | |||||||||
| warrants and convertible notes | - | 219,307 | (1,845,822 | ) | (1,895,344 | ) | |||
| Amortization of deferred loss | (1,018,282 | ) | (2,761,152 | ) | (2,241,846 | ) | (5,026,442 | ) | |
| (763,596 | ) | 44,131 | (4,305,485 | ) | 8,048,559 | ||||
| LOSS BEFORE TAX | (8,977,598 | ) | (9,048,410 | ) | (19,137,008 | ) | (11,216,557 | ) | |
| Tax recovery | - | 15,396 | - | 16,128 | |||||
| LOSS FOR THE PERIOD | (8,977,598 | ) | (9,033,014 | ) | (19,137,008 | ) | (11,200,429 | ) | |
| OTHER COMPREHENSIVE LOSS FOR THE | |||||||||
| PERIOD | |||||||||
| Fair market value changes in convertible notes due to changes in own credit risk | - | (280,051 | ) | (216,938 | ) | (985,637 | ) | ||
| LOSS AND OTHER COMPREHENSIVE LOSS FOR THE PERIOD | |||||||||
| (8,977,598 | ) | (9,313,065 | ) | (19,353,946 | ) | (12,186,066 | ) | ||
| LOSS PER SHARE | |||||||||
| Basic and diluted loss per share | (3.29 | ) | (3.35 | ) | (7.03 | ) | (4.81 | ) | |
Contacts
Investors
Mike Cavanaugh
Westwicke/ICR
Email: Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Email: Sean.Leous@icrinc.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words expect, anticipate, estimate, may, will, should, intend, believe, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements contained in the news release may involve, but are not limited to, the expectation that the Company’s direct sales team will advance Reducer as a viable treatment for refractory angina in the UK, expectation that the Company will have an equally strong performance in the second half of 2022 and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 and in the Management’s Discussion and Analysis for the three and six months ended June 30, 2022 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What were Neovasc's Q2 2022 earnings results?
What is the current status of the COSIRA II trial for NVCN?
How much cash does Neovasc have as of Q2 2022?
What are the total expenses reported by Neovasc for Q2 2022?
What is Neovasc's plan for the UK market?
